Subclinical hepatitis C virus infection in Egyptian patients with rheumatic diseases: a multi-center study

Safaa Ali Mahran 1*, Alaa A. A. Mohamed 1, Dalia A. Nigm 2, M. Z. A. Abu Rahma 3, S. Abd-Elsalam 4, Hesham Hamoud 5, M. Hamdy 5, M. I. Risha 5, Ahmad Hamdy 5, Mohamed M. Abdelkareem 5, Saad Ghanem 5, Mohamed Hanafy 5, Abdelhafeez Moshrif 6, A. Fehr 7, Fatma H. ElNouby 8, A. Osman 9 and Manal M. Hassanien 1

Abstract

Background: Hepatitis C virus (HCV) infection is highly prevalent in Egypt. It was found to be 7.0% in a study done in 2015. There are some studies on the prevalence of HCV in rheumatoid arthritis, but to our knowledge, no previous study was done to detect it in other rheumatologic diseases. This study aims at detecting the prevalence of subclinical HCV infection in Egyptian patients with different rheumatic diseases. In the current study, eight hundred and three patients with different rheumatic diseases collected from five—geographically different—Egyptian rheumatology departments were studied. Patients with known current or previous HCV infection were excluded from the study. Screening for the positive anti-HCV antibodies was done for all patients. Screening for the presence of HCV ribonucleic acid (RNA) was done in patients with positive serology by reverse transcriptase-polymerase chain reaction.

Results: In the studied population, 675 (84.1%) patients were women. The mean age [± SD] was 44.2 [± 12.9] years. Hepatitis C antibody positivity was found in 73 (9.1%) of the patients, while 67 (8.3%) were having positive HCV-RNA quantitative PCR tests. The highest prevalence of seropositive HCV was found in drug-induced vasculitis (DIV) and cryo-vasculitis (100%), while in RA, HCV antibodies and PCR were found to be positive in 9.1% and 8.3% of patients, respectively.

Conclusions: Detection of the presence of HCV infection in 9.1 % of the studied middle-aged Egyptian patients with rheumatologic conditions points to the importance of screening for HCV in such population for early detection and intervention especially for those patients that are planned to start biologic therapy.

Keywords: Hepatitis C virus; Rheumatologic diseases; Reactivation; Egypt

Background

Hepatitis C virus (HCV) infection is a worldwide major health problem that has health-related and economic impacts including heavy costs. It was estimated to be the 7th leading cause of mortality worldwide and affects 150–170 million people, including 19 million in Europe [1, 2]. Egypt constitutes the country with the highest prevalence of HCV in the world, estimated nationally at 14.7% [3, 4].

The spectrum of clinical manifestations of HCV infection can range from asymptomatic hepatitis flares to chronic hepatitis with hepatic decompensation, fulminating hepatic failure, and death in about 70–80% of cases due to liver cirrhosis and liver cancer. Therefore, identifying patients at risk and early diagnosis is imperative to decrease its significant morbidity and mortality [5].

Hepatitis C virus is a hepatotrophic and lymphotropic agent that can trigger and sustain a clonal B cell expansion,
and produce different autoantibodies causing a broad spectrum of autoimmune and lympho-proliferative disorders. This can complicate the differential diagnosis between primitive and HCV-related rheumatic disorders [6]. Extrahepatic manifestations of HCV including rheumatologic disorders have been reported in up to two thirds of infected patients [7, 8]. These manifestations may include frank autoimmune and rheumatic diseases (such as myalgia, arthralgia, arthritis, vasculitis, and sicca syndrome) which may dominate and complicate the course of the disease; moreover, treatment with biologic agents could reactivate latent HCV infection [9].

Having been known with the highest HCV prevalence, yet the rate of rheumatic diseases associated with subclinical HCV remains poorly studied in Egypt. Therefore, we aimed to unveil the prevalence of subclinical HCV in Egyptian populations with different rheumatic diseases. We hypothesized that the rheumatic diseases may increase the vulnerability of the patients to get infected with HCV more than their peers from the general non-rheumatic population. To our knowledge, this is the first study on the prevalence of subclinical seropositive HCV in Egyptian patients with this number of different rheumatic conditions.

**Methods**

**Study population and design**

Five university centers participated in this multi-center, observational cross-sectional study. These centers were chosen in a way that ensures pooling of the study subjects from nearly all over the country. The two Delta centers received patients from different northern areas in Egypt, while the remaining 3 Upper Egypt centers received patients from southern areas in Egypt.

Each center obtained approval to this study from its Local Ethics Committee, respecting the ethical standards in the Helsinki Declaration of 1975, as revised in 2000. The clinical trial registration number is NCT03587714. Written consent was obtained from each participating subject prior to enrolment.

The study subjects were recruited from patients attending the outpatient Rheumatology Clinics in the aforementioned centers. Patients aged less than 18, pregnant females, patients with current or past history of viral hepatitis, and patients with secondary rheumatic manifestations or with end-organ failure were excluded.

The study was carried out in a 4 months’ duration, starting from the beginning of May to the end of August 2017.

Demographic and clinical data were gathered from all patients using a unified questionnaire (Table 1). Diagnoses were made by a qualified rheumatologist according to the fulfillment of diagnostic criteria of different rheumatic diseases (e.g., ACR-EULAR 2012 criteria for RA, SLICC for lupus).

Routine lab works, e.g., CBC, ESR, CRP and other rheumatic diseases’ specific autoantibodies to assist diagnoses of primary rheumatic diseases, were done. Liver function tests and HCV antibodies were also done for all participants. HCV-RNA quantitative PCR test was done for patients with positive HCV antibodies tests.

**Anti-HCV antibodies quantification**

Serum samples withdrawn from patients were stored at −20 °C. Serum anti-HCV antibodies levels were analyzed on ARCHITECT i1000SR Immunoassay (Abbott Diagnostics, Europe), using chemiluminescence/magnetic particle. The results were represented as serum to cut-off ratio (S/CO). All samples were tested in duplicates.

**HCV-RNA quantification**

Serum HCV-RNA levels were analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) on 7500 Fast Real-Time instrument. The results were represented as international unit per milliliter (IU/mL). All samples were tested in duplicates.

**Statistical analysis**

The descriptive data were presented as number and percentage (N, %), and mean and standard deviation (mean, SD). Cross tabulation was done by chi-square test. All statistical analyses were carried out using the Statistical Package for Social Science (SPSS) version 24 (SPSS Inc.; Chicago, IL, USA).

**Results**

A total of 803 rheumatic patients from five different Rheumatology centers in Egypt were recruited in this study. The mean age of our patients was 44.2 ± 12.9 years, most of them were females 675 (84.1%), and the mean disease duration was 7.3 ± 6 years. Hepatitis C positivity was found in 73 (9.1%) of the 3

Over half of the patients 483 (66.1%) were diagnosed to have rheumatoid arthritis, while systemic lupus was
diagnosed in 96 (12%) patients. Forty-four patients (5.5%) had osteoarthritis (OA) and Behcet’s disease was found in 27 (3.4%) patients. Only 3 patients (0.4%) were having polyarthritis of no cause except vitamin D deficiency with mean serum level of 12.03 ± 2.5 ng/ml. The rest of the patients had other rheumatic diseases with different frequencies as shown in Table 2.

Table 2 Frequency of rheumatic diseases in the cohort

| Rheumatic diseases | Total n = 803 |
|--------------------|--------------|
| RA                 | 483 (60.1%)  |
| SLE                | 96 (1.2%)    |
| OA                 | 44 (5.5%)    |
| Non-specific rheumatic manifestations* | 36 (4.5%) |
| BD                 | 27 (3.4%)    |
| AS                 | 17 (2.1%)    |
| SSc                | 14 (1.7%)    |
| SS                 | 11 (1.4%)    |
| FMS                | 10 (1.2%)    |
| CPPD               | 9 (1.1%)     |
| Gout               | 7 (0.9%)     |
| Overlap syndrome (RA+SLE) | 7 (0.9%) |
| SPA                | 6 (0.7%)     |
| IDM                | 6 (0.7%)     |
| PsA                | 5 (0.6%)     |
| Cryo-vasculitis    | 4 (0.5%)     |
| Sarcoïdosis        | 3 (0.4%)     |
| PA                 | 3 (0.4%)     |
| GCA+PMR            | 2 (0.2%)     |
| JIA                | 2 (0.2%)     |
| MCTD               | 2 (0.2%)     |
| Vasculitis         | 2 (0.2%)     |
| WG                 | 1 (0.1%)     |
| MPA                | 1 (0.1%)     |
| DIV                | 1 (0.1%)     |
| Palindromic rheumatism | 1 (0.1%) |
| Overlap syndrome (RA+SSc) | 1 (0.1%) |
| AOSD               | 1 (0.1%)     |
| APS                | 1 (0.1%)     |

RA rheumatoid arthritis, SLE systemic lupus erythematosus, OA osteoarthritis, BD Behcet’s disease, AS ankylosing spondylitis, SSc systemic sclerosis, SS Sjogren’s syndrome, FMS fibromyalgia syndrome, CPPD calcium pyrophosphate dehydrogenate deposition disease, SPA spondyloarthropathy, IDM inflammatory dermatomyositis, PsA psoriatic arthritis, PA polyarthritis due to vitamin D deficiency, GCA giant cell arteritis, PRR polyarthritis rheumatica, JIA juvenile-onset inflammatory arthritis, MCTD mixed connective tissue disease, WG Wagner’s granulomatosis, MPA microscopic polyangiitis, DIV drug-induced vasculitis, AOSD adult-onset Still’s disease, APS antiphospholipid syndrome

*Non-specific rheumatic manifestations included tendinitis, tendinopathy, bursitis, osteomalacia, bone pain, non-inflammatory back pain, or neuropathic pain

The distribution of cases with positive HCV antibodies and positive PCR among the 5 different centers is demonstrated in Table 3. All patients with positive HCV antibody had positive PCR testing except in 3 centers where 8 patients had positive antibody and negative PCR. In one center, isolated positive PCR was found in a total of 2 patients.

The distribution of seropositive HCV and positive PCR among different rheumatic conditions is presented in Table 4. The highest prevalence of seropositive HCV was found in drug-induced vasculitis (DIV) and cryo-vasculitis (100%), followed by polyarthritis (66.7%) and gout (28.6%). In RA, HCV antibodies and PCR were found to be positive in 8.4% and 8.3% of patients, respectively. Negative HCV antibodies were reported in some cases including Behcet’s disease, calcium pyrophosphate dehydrogenate deposition disease (CPPD), Sjogren’s, sarcoidosis, mixed connective tissue diseases, juvenile-onset idiopathic arthritis (JIA), Wagner’s granulomatosis (WG), palindromic rheumatism, primary fibromyalgia, adult-onset Still’s disease, and anti-phospholipid syndrome.

Discussion

Egypt was reported previously to be among the areas with the highest prevalence of HCV infection in the world. It accounted for up to 40% in some areas [10–13]. However, the prevalence of this infection has not been determined in rheumatic diseases where it could have a role in their evolution or management. To our knowledge, this is the first study on the prevalence of subclinical seropositive HCV in Egyptian patients with this number of different rheumatic conditions.

In this study, the prevalence of positive HCV antibodies and positive PCR in the studied population was found to be 9.1% and 8.3%, respectively. In a recent epidemiological study on Egyptian populations, patients with rheumatic conditions were classified as “Special clinical population” among 6 groups of populations at risk of exposure to hepatitis C infection. In this population, the prevalence of positive hepatitis C antibodies ranged from 6.7 to 96.1% with a median of 38.0%. This very wide range can be explained by the fact that they included in this study patients with dermatological diseases and non-hepatic malignancies [14].

The pooled mean prevalence of anti-HCV antibodies among the same population was 35.0% (95% CI = 27.3–43.1%). Furthermore, the incidence of hepatitis C infection was found to be higher in the residents of the villages of the Nile Delta compared with residents of the villages of Upper Egypt (10.2 per 1.000 persons versus 0.8 per 1.000 persons, respectively). Their findings suggest that HCV screening in the “special clinical population” should be given a priority [14].
In agreement with the previous finding, we recorded a high prevalence of positive HCV antibodies and PCR (9.9%) each in the patients recruited from center 2 (of a Delta city), while the lowest prevalence (3.3%, 6.6% respectively) was recorded in patients recruited from center 4 (Upper Egypt).

The association between HCV infection and rheumatic diseases especially RA has been reported in many studies. The prevalence of chronic HCV infection in rheumatic patients varied according to the study site, which could reflect differences in the prevalence of HCV among different countries. Some Brazilian and Spanish studies reported the high prevalence of seropositive HCV infection in patients with rheumatic diseases [15, 16].

In the current study, the prevalence of positive HCV antibodies and positive PCR in RA patients was 8.5% and 8.3%, respectively. This is markedly higher than what was reported by Maillefert et al. who found that positive HCV antibodies and positive PCR among RA patients were 0.85% and 0.42%, respectively [17].

This great difference could be explained by the endemicity of HCV in Egypt. There is some evidence of the critical role of the liver in modulating the immune response in chronic inflammatory and autoimmune conditions [18–20].

It was denoted in the literature that autoimmune and lympho-proliferative diseases are well-known HCV-related disorders [21]. However, many studies failed to find a positive association between HCV infection and RA, with no support for the participation of HCV in the pathogenesis of RA [15, 17, 22]. A nationwide study done in Taiwan reported that patients with HCV infection were at higher risk of developing RA later [23].

Some studies found that arthralgia and arthritis were the most common extrahepatic manifestations of chronic HCV infection [24, 25]. Others claim that there is high prevalence of seropositive HCV among rheumatologic patients [15, 16]. This goes in line with our finding where seropositive HCV was found in (100%) of patients with drug-induced vasculitis and cryo-vasculitis, followed by polyarthralgia (66.7%) and gout (28.6). A possible explanation could be that the state of chronic viremia may trigger these diseases in genetically predisposed persons. Two out of the 3 (66.7%) patients with polyarthralgia were positive for HCV antibodies and PCR. Several studies had reported the high prevalence of vitamin D deficiency in all chronic hepatic diseases irrespective of their etiology [26–28]. Serum vitamin D level < 20 ng/ml was found to be highly prevalent in patients with chronic hepatitis B and C worldwide [29]. Furthermore, vitamin D deficiency was delineated to contribute in the pathogenesis of hepatitis B and C and lead to progression of hepatic inflammation and fibrosis [30].

It was reported that clinically evident vasculitis occurs in less than 5% of HCV infected subjects with typical manifestations of purpura, weakness, and arthralgia [6, 31, 32]. Although circulating mixed cryoglobulins are detected in 40–60% of patients chronically infected with HCV, overt cryo-vasculitis is observed in only 5–10% of cases. HCV infection represents the cause of cryo-vasculitis in 70–80% of cases as Cacoub and his colleagues found [33–35].

### Table 3 Distribution of seropositive HCV and positive PCR patients among the study centers

| Study center       | Total patients | Positive anti-HCV, n (%) | Positive HCV PCR n (%) |
|--------------------|----------------|--------------------------|------------------------|
| Delta Centers      |                |                          |                        |
| Center 1           | 101            | 10 (9.9)                 | 10 (9.9)               |
| Center 2           | 387            | 36 (9.3)                 | 31 (8)                 |
| Upper Egypt Centers|                |                          |                        |
| Center 3           | 215            | 21 (9.8)                 | 19 (8.8)               |
| Center 4           | 61             | 2 (3.3)                  | 4 (6.6)                |
| Center 5           | 39             | 4 (10.3)                 | 3 (7.7)                |
| Total number       | 803            | 73 (9.1)                 | 67 (8.3)               |

HCV hepatitis C virus, PCR polymerase chain reaction, n number

### Table 4 Distribution of the anti-HCV-positive and PCR-positive patients among different diseases

| Diagnosis                        | Anti-HCV positive | Positive PCR |
|----------------------------------|-------------------|--------------|
| AS                               | 2 (11.8%)         | 0            |
| Cryo-vasculitis                  | 4 (100%)          | 3 (75%)      |
| DIV                              | 1 (100%)          | 1 (100%)     |
| Gout                             | 2 (28.6%)         | 2 (28.6%)    |
| OA                               | 7 (15.9%)         | 4 (9.1%)     |
| PA                               | 2 (66.7%)         | 2 (66.7%)    |
| PsA                              | 1 (20%)           | 1 (20%)      |
| RA                               | 41 (8.5%)         | 40 (8.3%)    |
| SLE                              | 5 (5.2%)          | 4 (4.2%)     |
| SSc                              | 1 (7.1%)          | 1 (7.1%)     |
| Non-specific rheumatic manifestations | 7 (19.4%) | 9 (25%) |
| Total                            | 73 (9.1%)         | 67 (8.3%)    |

AS ankylosing spondylitis, DIV drug-induced vasculitis, OA osteoarthritis, PA polyarthralgia due to vitamin D deficiency, PsA psoriatic arthritis, RA rheumatoid arthritis, SLE systemic lupus erythematosus, SSc systemic sclerosis

Non-specific rheumatic manifestations included tendinitis, tendinopathy, bursitis, osteomalacia, bone pain, non-inflammatory back pain, or neuropathic pain
We did not detect HCV antibodies in some rheumatic diseases including Behcet’s disease, CPPD, Sjogren’s, sarcoidosis, mixed connective tissue diseases, JIA, WG, palindromic rheumatism, primary fibromyalgia, adult-onset Still’s disease, and antiphospholipid syndrome.

Although anti-HCV antibodies were found in 15.2% of fibromyalgia patients in a Spanish study [36], the increased prevalence of HCV infection in such condition was not confirmed by other studies [37]. However, HCV infection should be kept in mind as a possible cause of secondary fibromyalgia [7].

Detection of seropositive HCV antibodies denotes either active or past infection while detecting the state of viremia assessed by PCR test is a powerful indicator of chronic HCV infection. In this study, 8 patients with positive HCV antibodies were having negative PCR. In one center, isolated positive PCR was found in a total of 2 patients. The occurrence of positive PCR with negative HCV serology can be found but in very low prevalence [38, 39], and this denotes an occult HCV infection, which necessitates testing of both HCV antibodies and PCR in all patients.

This study had some limitations including the small-sized population collected from some centers and the cross-sectional type of the study. The great difference in the number of patients in different disease groups was also a weak point. In this study, PCR testing was performed in seropositive HCV cases only, while it would be ideal to perform it in all the participants to detect occult HCV infection.

Conclusion

In conclusion, considering the endemicity of HCV in Egypt and the detection of positive antibody titer in 9.1% of the study patients, regular screening of Egyptian rheumatic patients for HCV infection may not be necessary for the detection of subclinical cases. Rheumatic diseases seem to have no effect on increasing the susceptibility of the patients to get infected by HCV. However, for patients planned to receive biologic therapy, it is a well-known recommendation to have screening for HCV and HBV before initiation of biological treatment.

Abbreviations

HCV: Hepatitis C virus; ACR: American College of Rheumatology; EULAR: European League Against Rheumatism; RA: Rheumatoid arthritis; SLICC: Systemic Lupus Collaborating Clinics; CBC: Complete blood count; ESR: Erythrocyte sedimentation rate; CRP: C reactive protein; RNA: Ribonucleic acid; SPSS: Statistical Package for Social Science; CPPD: Calcium pyrophosphate dehydrogenate deposition disease; WG: Wagner’s granulomatosis; PCR: Polymerase chain reaction; HBV: Hepatitis B virus; SLE: Systemic lupus erythematosus; OA: Osteoarthritis; BD: Behcet’s disease; AS: Ankylosing spondylitis; SSc: Systemic sclerosis; SS: Sjogren’s syndrome; FMF: Fibromyalgia syndrome; SPA: Spondyloarthropathy; IDM: Inflammatory dermatomyositis; PsA: Psoriatic arthritis; PA: Polyanarthralgia associated with hypervitaminosis D; GCA: Giant cell arteritis; PMR: Polymyalgia rheumatica; JIA: Juvenile-onset inflammatory arthritis; MCTD: Mixed connective tissue disease; MPA: Microscopic polyangiitis; DIV: Drug-induced vasculitis; AOSD: Adult-onset Still’s disease; APS: Antiphospholipid syndrome

Acknowledgements

Not applicable

Authors’ contributions

S M: Conception and design, critical revision of the submitted protocol for important intellectual content, acquisition of data, analysis and interpretation of data, and writing the manuscript. A M: Statistical analysis. D N and O A: Laboratory work out. M R: Conception, design, and administrative tasks. S A: Critical revision of the submitted protocol for important intellectual content and revision of the manuscript. H H: Administrative and supervision. M H, M R, A H, M M A, S G, M H, A M, A F, and F E: Acquisition of data, analysis, and interpretation of data. M H: Conception and design, acquisition of data, analysis and interpretation of data, critical revision of the submitted protocol for important intellectual content, and drafting of the submitted protocol. All authors read and approved the final manuscript.

Funding

No funding from an external organization or body was needed.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This study has been approved by the local ethics committee of Faculty of Medicine, Assiut University, and each collaborating center attained approval from its local ethical committee and conforms to the guidelines of the Declaration of Helsinki.

Final approval of the research from the local ethical committee was obtained under the ID number of 17300384 at April 22, 2017 Clinical trial registration no. NCT03587714

Written consents were collected from the participants before enrollment in the study.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Author details

1Rheumatology, Rehabilitation and Physical Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt. 2Clinical Pathology, Assiut University, Assiut, Egypt. 3Clinical Pathology, Aswan University, Aswan, Egypt. 4Clinical and Chemical Pathology, Aswan University, Aswan, Egypt. 5Clinical and Chemical Pathology, Aswan University, Asswan University, Asswan, Egypt. 6Clinical Pathology, Assiut University, Assiut, Egypt. 7Rheumatology and Rehabilitation, Helwan University, Cairo, Egypt. 8Rheumatology and Rehabilitation, Al-Azhar University, Cairo, Egypt. 9Rheumatology and Rehabilitation, Aswan University, Aswan, Egypt. 10Rheumatology and Rehabilitation, Helwan University, Cairo, Egypt. 11Rheumatology and Rehabilitation, Aswan University, Asswan, Egypt. 12Rheumatology and Rehabilitation, Helwan University, Cairo, Egypt. 13Rheumatology and Rehabilitation, Aswan University, Aswan, Egypt.

Received: 21 April 2020 Accepted: 18 May 2020

Published online: 08 September 2020

References

1. Lavanchy D (2011) Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17(2):107–115.
2. Negro F (2014) Epidemiology of hepatitis C in Europe. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 46(5):S158–S164
3. Ahmed OA, SalWat E, Khalifa MO et al (2018) Sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 infection in a cohort of Egyptian patients: an experiment the size of Egyptian village. Int J Hepatol. 2018:1–5
4. Abd-Elbalam S, Sharaf-Eldin M, Sollman S et al (2018) Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol 163(1):S1–S6
5. Antonelli A, Ferris C, Galeazzi M et al (2008) HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol 26:539–547
6. Ferris C, Sebastiani M, Giuggioli D et al (2015) Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer. World J Hepatol 7:327–343
